View in EDS HTML Full Text PDF Full Text

177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.

Saved in:
Bibliographic Details
Title: 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.
Authors: Hallqvist, Andreas1,2 (AUTHOR) andreas.hallqvist@vgregion.se, Brynjarsdóttir, Elva1,2 (AUTHOR), Krantz, Tomas1 (AUTHOR), Sjögren, Marie1 (AUTHOR), Svensson, Johanna1,2 (AUTHOR), Bernhardt, Peter3,4 (AUTHOR)
Source: Journal of Nuclear Medicine. May2025, Vol. 66 Issue 5, p707-712. 6p.
Database: Engineering Source
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: egs
DbLabel: Engineering Source
An: 186886042
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: <superscript>177</superscript>Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hallqvist%2C+Andreas%22">Hallqvist, Andreas</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<i> andreas.hallqvist@vgregion.se</i><br /><searchLink fieldCode="AR" term="%22Brynjarsdóttir%2C+Elva%22">Brynjarsdóttir, Elva</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krantz%2C+Tomas%22">Krantz, Tomas</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sjögren%2C+Marie%22">Sjögren, Marie</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Svensson%2C+Johanna%22">Svensson, Johanna</searchLink><relatesTo>1,2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bernhardt%2C+Peter%22">Bernhardt, Peter</searchLink><relatesTo>3,4</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Nuclear+Medicine%22">Journal of Nuclear Medicine</searchLink>. May2025, Vol. 66 Issue 5, p707-712. 6p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=186886042
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2967/jnumed.124.268902
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 707
    Titles:
      – TitleFull: 177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hallqvist, Andreas
      – PersonEntity:
          Name:
            NameFull: Brynjarsdóttir, Elva
      – PersonEntity:
          Name:
            NameFull: Krantz, Tomas
      – PersonEntity:
          Name:
            NameFull: Sjögren, Marie
      – PersonEntity:
          Name:
            NameFull: Svensson, Johanna
      – PersonEntity:
          Name:
            NameFull: Bernhardt, Peter
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: May2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 01615505
          Numbering:
            – Type: volume
              Value: 66
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of Nuclear Medicine
              Type: main
ResultId 1